Atlas Trials

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Clinical trial NCT05083208 · TERMINATED

Trial details

NCT number
NCT05083208
Sponsor
Henan Cancer Hospital
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Peripheral T-Cell Lymphoma
Start date
2022-02-20
Primary completion
2024-06-30
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.